Procyon Advisors LLC Buys 67,329 Shares of Haleon plc (NYSE:HLN)

Procyon Advisors LLC increased its position in Haleon plc (NYSE:HLN - Free Report) by 41.3% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 230,240 shares of the company's stock after buying an additional 67,329 shares during the quarter. Procyon Advisors LLC's holdings in Haleon were worth $2,196,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. Fortitude Family Office LLC acquired a new position in Haleon in the 3rd quarter valued at approximately $28,000. Versant Capital Management Inc increased its holdings in Haleon by 2,029.1% in the fourth quarter. Versant Capital Management Inc now owns 3,513 shares of the company's stock valued at $34,000 after purchasing an additional 3,348 shares during the period. Toronto Dominion Bank raised its position in Haleon by 3,470.0% during the 3rd quarter. Toronto Dominion Bank now owns 3,570 shares of the company's stock worth $38,000 after purchasing an additional 3,470 shares during the last quarter. Prospera Private Wealth LLC acquired a new position in Haleon during the 3rd quarter worth about $57,000. Finally, Brown Brothers Harriman & Co. grew its position in shares of Haleon by 21.4% in the 2nd quarter. Brown Brothers Harriman & Co. now owns 7,569 shares of the company's stock valued at $63,000 after buying an additional 1,334 shares during the last quarter. Institutional investors own 6.67% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the company. UBS Group upgraded Haleon to a "strong-buy" rating in a research report on Tuesday, October 1st. Sanford C. Bernstein downgraded shares of Haleon from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 8th. Finally, Morgan Stanley cut shares of Haleon from an "overweight" rating to an "equal weight" rating in a research report on Friday, January 10th. Three equities research analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average target price of $10.95.

Haleon Trading Up 0.5 %

HLN stock traded up $0.05 during mid-day trading on Friday, reaching $9.24. The company's stock had a trading volume of 21,226,372 shares, compared to its average volume of 5,607,522. Haleon plc has a 12 month low of $7.89 and a 12 month high of $10.80. The company has a current ratio of 0.84, a quick ratio of 0.58 and a debt-to-equity ratio of 0.44. The business's 50 day moving average price is $9.54 and its 200 day moving average price is $9.69. The company has a market cap of $41.80 billion, a price-to-earnings ratio of 27.16, a price-to-earnings-growth ratio of 2.52 and a beta of 0.29.

Haleon Profile

Haleon plc, together with its subsidiaries, engages in the research, development, manufacture, and sale of various consumer healthcare products in North America, Europe, the Middle East, Africa, Latin America, and the Asia Pacific. The company provides oral health products, such as toothpastes, mouth washes, and denture care products under the Sensodyne, Polident, Parodontax, Biotene brands; and vitamins, minerals, and supplements under Centrum, Emergen-C, Caltrate brands.